Type of information: Private placement
Company: RegenXBio (USA - MD)
Amount: $87.2 million
Funding type: private placement
- • On April 26, 2017, Regenxbio announced that the underwriters of its public offering of common stock have purchased an additional 555,000 shares of common stock at a price of $20.50 per share, before deducting the underwriting discount, in connection with the exercise in full of their option to purchase additional shares. As a result of the exercise of this option to purchase additional shares, the total number of shares of Regenxbio common stock sold in the offering increased to 4,255,000 shares, and the total gross proceeds to Regenxbio from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Regenxbio, increased to approximately $87.2 million.
• On March 21, 2017, Regenxbio announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at the price of $20.50 per share before underwriting discounts and commissions. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.85 million. This offering is expected to close on March 27, 2017, subject to customary closing conditions. The company has granted the underwriters a 30-day option to purchase an additional 555,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
- Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers. Chardan Capital Markets, is acting as co-manager of the offering.
- • On March 21, 2017, Regenxbio announced that it intends to offer and sell, subject to market conditions, $75,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Therapeutic area: Rare diseases - Genetic diseases